Skip to navigation Skip to content

CD30 positive systemic anaplastic large cell lymphoma program in Pharmaceutical Benefits Scheme (PBS) 012-18051139

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin for patients with CD30 positive systemic anaplastic large cell lymphoma (sALCL).

CD30 positive systemic anaplastic large cell lymphoma and listing dates

CD30 positive systemic anaplastic large cell lymphoma (sALCL) is a rare type of non-Hodgkin’s lymphoma.

Listing dates are:

  • brentuximab vedotin - 1 December 2014.

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex Drugs Programs team and choose the option relevant to the condition treated.

The Resources page contains links to application forms, contact details, item and restriction codes, the PBS schedule and the Services Australia website.

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing Written Authority requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs